IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma Patients.
MDSC
cytokine
immunosuppression
long-term survival
melanoma
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2019
2019
Historique:
received:
25
06
2019
accepted:
25
10
2019
entrez:
30
11
2019
pubmed:
30
11
2019
medline:
30
11
2019
Statut:
epublish
Résumé
We sought to identify tumor-secreted factors that altered the frequency of MDSCs and correlated with clinical outcomes in advanced melanoma patients. We focused our study on several of the many factors involved in the expansion and mobilization of MDSCs. These were identified by measuring circulating concentrations of 13 cytokines and growth factors in stage IV melanoma patients (
Identifiants
pubmed: 31781510
doi: 10.3389/fonc.2019.01223
pmc: PMC6857649
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1223Informations de copyright
Copyright © 2019 Tobin, Jordan, Kapoor, Spongberg, Davis, Vorwald, Couts, Gao, Smith, Borgers, Robinson, Amato, Gonzalez, Lewis, Robinson, Borges and McCarter.
Références
Oncotarget. 2014 Sep 30;5(18):8716-28
pubmed: 25238263
Cancer Cell. 2016 Jun 13;29(6):832-845
pubmed: 27265504
Cell Metab. 2016 Nov 8;24(5):672-684
pubmed: 27829137
Oncotarget. 2017 Jun 13;8(24):38378-38388
pubmed: 28418913
Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4221-6
pubmed: 24591638
Clin Cancer Res. 2016 Aug 1;22(15):3924-36
pubmed: 26957562
Cancer Immunol Immunother. 2013 Nov;62(11):1711-22
pubmed: 24072401
Cancer Lett. 2018 Oct 1;433:147-155
pubmed: 29969659
Clin Cancer Res. 2016 Dec 1;22(23):5661-5672
pubmed: 27178742
N Engl J Med. 2013 Apr 4;368(14):1365-6
pubmed: 23550685
Cancer Res. 2014 Sep 15;74(18):5057-69
pubmed: 25082815
J Clin Invest. 2014 Sep;124(9):3901-12
pubmed: 25133426
Protein Cell. 2016 Feb;7(2):130-40
pubmed: 26797765
J Exp Med. 2017 Jun 5;214(6):1691-1710
pubmed: 28450382
Cancer Res. 2018 Sep 1;78(17):5011-5022
pubmed: 29967259
J Clin Invest. 2013 Apr;123(4):1580-9
pubmed: 23454751
Cancer Cell. 2012 Jun 12;21(6):822-35
pubmed: 22698406
Innate Immun. 2013 Jun;19(3):328-36
pubmed: 23160385
Clin Cancer Res. 2014 Nov 15;20(22):5697-707
pubmed: 25224278
Cell Death Differ. 2000 Mar;7(3):329-30
pubmed: 10866494
J Leukoc Biol. 2017 Aug;102(2):381-391
pubmed: 28179538
Immunol Cell Biol. 2017 Jul;95(6):538-548
pubmed: 28108746
Ann Oncol. 2017 Aug 1;28(8):1988-1995
pubmed: 28595336
Cancer Immunol Res. 2017 Jan;5(1):3-8
pubmed: 28052991
JCI Insight. 2017 Nov 2;2(21):
pubmed: 29093275
Oncogene. 2019 Jan;38(4):533-548
pubmed: 30158673
Front Immunol. 2018 Jun 11;9:1310
pubmed: 29942309
Front Immunol. 2017 Dec 15;8:1840
pubmed: 29326716
Cancer Immunol Immunother. 2012 Feb;61(2):145-155
pubmed: 21853302
Immunity. 2018 Jan 16;48(1):91-106.e6
pubmed: 29343444
Cell Rep. 2014 Aug 21;8(4):1037-48
pubmed: 25127139
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
Cancer Immunol Immunother. 2017 Apr;66(4):503-513
pubmed: 28108766
Int Immunopharmacol. 2018 Oct;63:282-291
pubmed: 30121453
Clin Cancer Res. 2018 Nov 1;24(21):5407-5421
pubmed: 29959142
Semin Immunol. 2014 Feb;26(1):38-47
pubmed: 24602448
Cell. 2016 Oct 6;167(2):397-404.e9
pubmed: 27667683
Cancer Immunol Res. 2018 Oct;6(10):1246-1259
pubmed: 30082413
Neoplasia. 2013 Jul;15(7):848-62
pubmed: 23814496